Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia
Shampa Das, Richard J. Fitzgerald, Asad Ullah, Marcin Bula, Andrea M. Collins, Elena Mitsi, Jesús Reiné, Helen Hill, Jamie Rylance, Daniela M. Ferreira, Karen Tripp, Andrea Bertasini, Samantha Franzoni, Mameli Massimiliano, Omar Lahlou, Paola Motta, Philip Barth, Patrick Vélicitat, Philipp Knechtle, William Hope
Abstract
Cefepime-enmetazobactam is a novel β-lactam–β-lactamase inhibitor combination with broad-spectrum antimicrobial activity against a range of multidrug-resistant Enterobacteriaceae . This agent is being developed for a range of serious hospital infections. An understanding of the extent of partitioning of β-lactam–β-lactamase inhibitor combinations into the human lung is required to better understand the potential role of cefepime-enmetazobactam for the treatment of nosocomial pneumonia.